Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 11.3% – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price shot up 11.3% during mid-day trading on Friday . The company traded as high as $0.70 and last traded at $0.63. 151,239,068 shares traded hands during trading, an increase of 431% from the average session volume of 28,475,689 shares. The stock had previously closed at $0.57.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Sunday, December 15th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Price Performance

The company has a market capitalization of $114.30 million, a P/E ratio of -0.01 and a beta of 2.23. The business’s 50-day simple moving average is $0.20 and its 200 day simple moving average is $0.49. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, sell-side analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.